Kornimate/medical-research-clean huggingface dataset:
ureteropelvic junction obstruction in early childhood: comparison of surgical therapy and surveillance. a prospective, randomized, controlled multi-center study

Conditions: Unilateral Ureteropelvic Junction Obstruction

Summary: in this randomized trial surgical therapy and surveillance of ureteropelvic junction obstruction will be compared, regarding partial renal function.


Eligibility criteria:
inclusion criteria: * unilateral ureteropelvic junction obstruction * diameter of renal pelvis greater 12 mm * partial renal function of 35%-55% proofed by scintigraphy * urodynamically relevant decrease in renal drainage proofed by diuresis scintigraphy at the age of 4 weeks up to 6 months * abscence of clinical symptoms * healthy contralateral kidney exclusion criteria: * global decrease in renal function * renal dystopia * megaureter * vesico-ureteral reflux * progressive hydronephrosis * oligohydrammnion * voiding dysfunction * bilateral hydronephrosis * severe chronical illness * decrease of partial renal function of more then 5% during allocation
korean transient ischemic attack expression registry

Conditions: Transient Ischemic Attack

Summary: this study is to determine the clinical and neuroimaging characteristics of transient ischemic attacks in korean populations.


Eligibility criteria:
inclusion criteria: * clinical symptoms and signs consistent with transient ischemic attack * subject who admitted hospital within 24 hours after symptom onset * subjects who underwent mri (including diffusion-weighted images) and mra (or ct angiography) exclusion criteria: transient neurological symptoms due to * migraine aura * basilar migraine * seizures * syncope * peripheral vertigo * transient global amnesia

Keywords: transient ischemic attack
exploratory study to standard triple therapy with tegoprazan(by dose) in h. pylori positive patients

Conditions: Helicobacter Pylori Infection

Summary: this exploratory study is designed to compare safety and efficacy between a tegoprazan dose-specific standard triple therapy and lansoprazole standard triple therapy in h. pylori positive patients.

a randomized, double-blind, active-controlled, multicenter, therapeutic exploratory study to to evaluate the safety and efficacy of a standard triple therapy with tegoprazan and lansoprazole standard triple therapy in h. pylori positive patients, twice a day for 14 days.

Eligibility criteria:
inclusion criteria: * h. pylori positive at screening * subjects who have upper gastrointestinal disease exclusion criteria: * having received prior therapy for eradication of h. pylori * prior use of p-cab, proton pump inhibitors (ppis), h2 receptor blockers within 14 days * prior use of h. pylori eradication effective antibiotics, bismuth within 28 days
a study of the immunogenicity and safety of whole-cell pertussis containing vaccine administered concomitantly with rotateq™ (v260) or rotarix™ (v260-036)(withdrawn)

Conditions: Rotavirus Gastroenteritis; Diphtheria; Tetanus; Pertussis

Summary: this study will evaluate the immunogenicity and safety of the pertussis component of dtwp (whole-cell pertussis containing vaccine) when administered concomitantly with rotateq™ or rotatrix™.


Eligibility criteria:
inclusion criteria: * healthy infants exclusion criteria: * history of abdominal disorders, intestinal folding, or abdominal surgery * impaired immune system * prior administration of any rotavirus vaccine or dtwp/dtap * fever of \>= 38.1c (100.5f) at the time of vaccination * history of prior rotavirus infection, chronic diarrhea, or failure to thrive * evidence of active gastrointestinal illness
exercise, glucose kinetics, and the incretin effect

Conditions: Type 2 Diabetes

Summary: human volunteers will be stratified by oral glucose tolerance status: normal glucose tolerant, impaired glucose tolerant, and type 2 diabetic. all subjects will undergo 4 experimental trials: \[1\] an oral glucose tolerance test (ogtt) combined with infused and ingested stable isotopes of glucose to assess glucose kinetics. \[2\] a 1 hour bout of cycling exercise at 50% of maximum power output, immediately followed by the same ogtt combined with stable isotope glucose tracers used in trial 1. \[3\] an isoglycemic clamp to match the plasma glucose profile measured in trial 1. \[4\] a 1 hour bout of cycling exercise at 50% of maximum power output, immediately followed by an isoglycemic clamp to match the plasma glucose profile measured in trial 2. exercise-induced changes in oral glucose tolerance, glucose kinetics, insulin and glucagon secretion, and the incretin effect will be examined. the exercise responses will be compared between the subjects groups of different glucose tolerance status.


Eligibility criteria:
inclusion criteria: * age 18-60 years * bmi 18-35 kg/m2 exclusion criteria: * insulin dependency * pregnancy * presence or history of chronic cardiovascular, pulmonary, hepatic, renal, or hematological disease, or cancer * contraindication to physical activity as assessed by ecg

Keywords: exercise physical activity type 2 diabetes obesity incretin effect glp-1 gip insulin secretion glucagon beta-cell function disposition index
predictors of weight loss and metabolic health after bariatric surgery

Conditions: Obesity, Morbid; Insulin Sensitivity; Bariatric Surgery Candidate; Feeding Behavior

Summary: in this prospective study the investigators aim to identify preoperative predictors of improvement of metabolic health and weight loss after bariatric surgery focusing on inflammation, insulin sensitivity (in a subgroup of patients), glucoregulatory determinants, psychological traits, feeding behavior characteristics and cardiorespiratory fitness

obesity is the result of a complex interplay between genetic and epigenetic predisposition, environment, physical activity, nutrition and psychology. it is a debilitating disorder and a risk factor for the development of metabolic disorders such as dyslipidaemia, hypertension and hyperglycaemia as well as certain cancers. bariatric surgery has proven to be the most effective treatment for morbid obesity with established long-term results of weight loss, remission of comorbid conditions and the improvement of quality of life (qol). however, variability in these results after bariatric surgery is well known. identifying preoperative predictors of postoperative weight loss and metabolic health is of clinical priority. predictors could help further improve the efficacy of care for obesity by tailoring treatment to the individual, based on their predicted response and therefore optimize outcome after bariatric surgery.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent * patient is ≥ 18 and ≤ 75 years old * bmi ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity * scheduled for primary bariatric procedure: roux-en-y gastric bypass (rygb) or sleeve gastrectomy (sg) * stable weight 3 months prior to inclusion weight (\<10% change in body weight for 3 months prior to assessments) in order to be eligible to participate in the subgroup of this study, we will use the following inclusion criteria: * ability to provide informed consent * patient is ≥ 18 and ≤ 75 years old * bmi ≥ 40 kg/m2 or ≥ 35 kg/m2 with obesity related comorbidity * patients scheduled for rygb * patients who are insulin resistant (impaired fasting glucose (\> 5.6 mmol/l) or fasting insulin \> 74 pmol/l) * postmenopausal women (to prevent bias due to the effect of sex hormones on insulin sensitivity) exclusion criteria: * any actual medical condition except for obesity related health issues or well treated hypothyroidism * pregnancy anticipated in the first two years following surgery a potential subject who meet the following criteria will be excluded from participation in the subgroup of this study: * coagulation disorders and/or use anticoagulants * use of any medication except for statins, antihypertensives (except for angiotensine converting enzyme (ace)- or angiotensin receptor blockers) and thyroid hormone * diabetes mellitus type 2

Keywords: obesity bariatric surgery metabolic health weight loss predictors
a study of fortigel testosterone gel 2% in males with low testosterone

Conditions: Hypogonadism

Summary: low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. the medical name for low testosterone is hypogonadism. hypogonadism can be caused by many factors. symptoms include: decrease in libido, lack of energy and mood swings. the goal of testosterone replacement therapy is to return testosterone levels to the normal range and relieve symptoms. the purpose of this study is to evaluate the ability of fortigel testosterone gel 2% to maintain serum (blood) testosterone levels within the normal range in hypogonadal men aged 18 to 75 years. this will be determined by blood sampling at specified times during the study. the study is also intended to evaluate the tolerability of fortigel, which will be applied to the skin each day throughout the study period.


Eligibility criteria:
inclusion criteria: * men aged 18 - 75 years with primary or secondary hypogonadism as confirmed by: * single serum total testosterone concentration \< 250 ng/dl, or * two consecutive serum total testosterone concentrations \< 300 ng/dl (determined at least one week apart during the screening period). * has a bmi ≥ 22 kg/m2 and \< 35 kg/m2.

Keywords: hypogonadism
vitamin d and calcium study

Conditions: Spinal Cord Injury

Summary: vitamin d aids in the body's ability to absorb calcium, it is a vital component in bone formation and break down. reduced levels of vitamin d can indicate a vitamin deficiency and may depress serum calcium levels. the following is a list of common causes of vitamin d deficiency: lack of dairy products, alcohol usage, elderly, lack of exposure to sunlight, individuals with reduced mobility, gi malabsorption problems, dark complexion, severe liver damage, and renal failure. many of these factors can be found in individuals with spinal cord injury. sci results in disuse bone loss after acute injury, which continues with duration of injury. the goal of this study is to determine the effects of vitamin d and calcium supplements on calcium metabolism and vitamin d deficiency in individuals undergoing functional electrical stimulation (fes) stand retraining (srt).


Eligibility criteria:
inclusion criteria: * spinal cord injury (paraplegia or quadriplegia) * vitamin d deficiency * absolute deficient vitamin d \[25(oh)d\] \< 16 ng/ml * relative deficient vitamin d \[25(oh)d\] \<30ng/ml - participation in the fes/srt study at kessler institute for rehabilitation exclusion criteria: * history of kidney stones * history of bone disorders * currently pregnant

Keywords: spinal cord injury vitamin d deficiency functional electrical stimulation
conversion of labor analgesia for intrapartum cesarean delivery: dpe v cse v epidural

Conditions: Anesthesia; Analgesia

Summary: as the dural puncture epidural (dpe) is increasing in popularity for labor analgesia, it is important to understand how it impacts outcomes in parturients. prior studies have found epidural catheters placed via the combined-spinal epidural technique have greater success at surgical conversion for cesarean delivery than catheters placed via traditional techniques. the investigators aim to determine if epidural catheters placed by a dpe technique will also have an increased successful conversion for surgical anesthesia by conducting a retrospective review of all cd during the study period. if an association is found, this could be another benefit of dpe for labor analgesia.

electronic medical records will be searched for all intrapartum cesarean deliveries performed from february 1, 2017 through may 30, 2021 (mayo clinic) and from january 1, 2022 to december 31, 2022 (bc women's hospital). from this list, patients that had cesarean delivery with an epidural catheter will be identified and split into three groups based on the type of neuraxial block listed in the block document of the patient's medical record: group 1 - dural puncture epidural group 2 - epidural group 3 - combined spinal-epidural failure of epidural catheter conversion to surgical anesthesia at cesarean delivery will be defined by requirement of a second anesthetic at the time of surgery, including spinal or repeat epidural techniques or general anesthesia at the time of cesarean delivery data collection: all data will be collected retrospectively from the electronic medical record. 1. type of neuraxial block 2. size of needle used for dpe or cse: 25 g or 27 g 3. duration of time from epidural placement until cd (time of epidural placement; time of delivery) 4. number of epidural top-ups 5. type and amount of medication used for conversion to surgical anesthesia 6. urgency of cesarean delivery 7. airway documentation indicative of general anesthesia (if applicable) 8. length (time) of surgical procedure other data collected from patient electronic records will include: 1. maternal demographics: parity, number of prior cesarean deliveries, weight, height, bmi 2. fetal characteristics (birthweight, apgar scores) 3. indication for cesarean delivery 1. fetal distress (nrfht, fetal intolerance of labor) 2. failure of labor (failure to dilate, failure to descend) 3. failed operative vaginal delivery 4. maternal comorbidity 5. emergency (cord prolapse, abruption, uterine rupture) 4. anesthesiologist (fellowship trained: y/n) at time of cesarean delivery

Eligibility criteria:
inclusion criteria: 1. women with neuraxial labor analgesia (cse, dpe, or epidural) who have an intrapartum cesarean delivery 2. singleton gestation exclusion criteria: 1. no local anesthetic given in epidural for cesarean delivery (in emergency situation) 2. inadvertent dural puncture

Keywords: epidural cesarean parturient
antioxidant micronutrients in malaria

Conditions: Malaria

Summary: in the last decade, the prevalence of malaria has been escalating at an alarming rate, especially in africa. an estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% occur in children under 5 years of age in africa (who 1995). malaria is africa's leading cause of under-five mortality (20%) and constitutes 10% of the continent's overall disease burden. it accounts for 40% of public health expenditure, 30-50% of inpatient admissions, and up to 50% of outpatient visits in areas with high malaria transmission. antioxidant micronutrients have immunomodulatory role and may have suppressive activity.

the pathogenesis of plasmodial infection hinges on intracellular invasion of host erythrocyte and hepatocyte with possible generation of free radicals that may contribute to cellular membrane damage. this will make uninfected erythrocyte and hepatocyte to be more susceptible to merozoite invasion. zinc and selenium has immunomodulatory properties. they enhance cell-mediated immune response in malaria infection. this may help to adequately suppress schizont maturation and inhibit the release of merozoites. however, it is possible that they have a direct chemosuppressive or blood schizonticidal effect. the following research questions emanated from this hypothesis; 1. do the micronutrients in question have direct suppressive or schizonticidal effect? 2. can they be used as short course therapy with standard antimalarials in uncomplicated malaria? 3. is their effect enhanced when used in combination with each other or with standard antimalarials? 4. do they have any prophylactic benefit? 5. can their use alter the course of established malaria infection?

Eligibility criteria:
inclusion criteria: * age of \< 5 years * asexual parasitemia of between 1,000 and 100,000/µl * acute manifestation of malaria (e.g., history of fever in the preceding 24 hours or a temperature of \>37.5°c at baseline) * body weight between 5 and 30 kg * ability to tolerate oral therapy * informed consent by the legal representative of the subject (the parents, if possible), oral agreement of the child if appropriate * resident in the study area for a duration of at least 4 weeks exclusion criteria: * adequate antimalarial treatment within the previous 7 days * use of micronutrients in the last 2 weeks * antibiotic treatment for a concurrent infection * hemoglobin level of \<7 g/dl * hematocrit of \<25% * leukocyte count of \>15,000/µl * mixed plasmodial infection * severe malaria, any other severe underlying disease * concomitant disease masking assessment of the treatment response * inflammatory bowel disease, and any other disease causing fever

Keywords: antioxidants micronutrients malaria focus is to determine the effect of antioxidant micronutrients in malaria
visual perception in schizophrenia

Conditions: Schizophrenia Disorders; Bipolar Disorder; Schizo Affective Disorder

Summary: this study aims to identify novel markers of psychosis using electroencephalography (eeg).


Eligibility criteria:
inclusion criteria: * all subjects * aged 18-65 * 20/32 visual acuity or better (using in-house optical correction, if necessary) * an ability to speak english well enough to complete study assessments and to consent to the study * subjects with schizophrenia-spectrum disorder * meets dsm-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the structured interview for dsm-5 (scid-5). * subjects with bipolar disorder * meets dsm-5 diagnostic criteria for bipolar disorder (type i, ii, or unspecified) as confirmed by the structured interview for dsm-5 (scid-5). exclusion criteria: * all subjects * presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following: * subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent. * intellectual impairment (wrat-5 score \< 70) (at the discretion of experimenter); * actively intoxicated, as shown via patient self-report or staff report; * substance use disorder in the past 3 months; * subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview or any suicide attempt in 30 days prior to screening); * subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation. * being in a current manic state * head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter). * subject has had electroconvulsive therapy (ect) in the past 8 weeks; * diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. diagnosed with pervasive developmental disorder (phone screen or medical records) * lazy eye or squint or other known ocular pathology * healthy control subjects * any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure); * daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. first-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * case-match control non-ill subjects * any lifetime psychotic disorder (as assessed by scid/or ssd); * recurrent depressive episodes or being in a current depressive episode (as assessed by scid/or ssd) * persistent threshold psychotic symptoms * history of psychiatric hospitalization; * daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days * first-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * bipolar subjects * persistent threshold psychotic symptoms
determine the bioequivalence of two formulations of tamsulosin hcl capsules in fasted male.

Conditions: Prostatic Hyperplasia

Summary: a bio-equivalence of 2 different capsule formulations in fasted subjects


Eligibility criteria:
inclusion criteria: healthy male volunteers 18 years and older exclusion criteria: history of hypersensitivity or allergy to the ipm or its excipients or any related medication
preemptive analgesia with oxycontin versus placebo before surgery for long bone fractures

Conditions: Fractures

Summary: we would like to check whether pre-operative administration of an oral controlled-release opioid formulation (oxycodone hydrochloride (oxycontin)) could result in a clear effect of preemptive analgesia.

preemptive analgesia is based on the concept of treating pain before inflicting the painful stimulus. one suggested mechanism is that transmission of pain signals is altered when the patient is treated before infliction of noxious stimulation. that prevents changes from happening in the nervous system, making transformation from acute to chronic pain ("central sensitization") less likely, and thus reducing post operative pain. clinically, good post operative pain control has been shown to be an effective method for hastening patient convalescence and discharge. it makes part of a general approach aiming to accelerate surgical recovery through earlier enteric feeding and ambulation oxycontin tablets deliver oxycodone at a controlled release manner, over 12 hours. after oral administration oral bioavailability is 60-87%. a biphasic absorption pattern is observed, describing the initial (0.6 hours) and prolonged (6.9 hours) release of oxycodone from the oxycontin tablets. clinical analgesia is observed within 1 hour of administration. we believe that this mode of oral drug release is more appropriate for the perioperative pain treatment of patients undergoing short to medium term operations: with timely administration, the first absorbed part of the drug reaches the plasma before infliction of the noxious stimuli, possibly counteracting primary sensitization, and the second part absorbed, acts on post operative ongoing pain, possibly counteracting more advanced stages of neuronal plasticity. study hypothesis: our hypothesis is that post operative pain will be lowered by pre-operative administration of oxycontin. when comparing the two groups we will look for differences in observed parameters, especially vas numbers, time to first analgesic request, post operative analgesic requirements, time to first oral intake and length of hospitalization, to confirm or deny our hypothesis.

Eligibility criteria:
inclusion criteria: 1. patient consent. 2. age 18 years to 60 years. 3. isolated limb bone fracture/s. exclusion criteria: 1. patient refusal. 2. age 61 years and older. 3. known allergy to study medication. 4. multiple bone fractures in different limbs. 5. multiple trauma. 6. oncological patients. 7. respiratory depression / respiratory insufficiency / hypercarbia. 8. acute bronchial asthma. 9. cns depression / hallucinations. 10. alzheimer / dementia. 11. known convulsive disorder. 12. prostate hypertrophy. 13. paralytic ileus. 14. renal dysfunction (plasma creatinine \> 1.5). 15. liver dysfunction. 16. adrenocortical insufficiency. 17. hypothyroidism. 18. pancreatitis. 19. pregnancy and lactating. 20. drug abuse, current or in the past. 21. alcohol abuse on admission to operating room.

Keywords: long bone fracture open fractures closed fractures trauma